European Commission Cracks Down on Delayed Generics

The European Commission found that Danish pharmaceutical company Lundbeck had worked with companies such as Ranbaxy and Merck to delay market entry od less expensive generic versions of their antidepressant drug, citalopram. The case mirrors a decision made earlier this week by the United States Supreme Court regarding "pay-for-delay" tactics. Read the full story.